Is Angiotensin Receptor-Neprilysin Inhibitor (ARNI) the Magic Wand? A Single-Centre, Double-Blind, Randomised, Active-Controlled Study to Evaluate the Efficacy and Safety of ARNI vs. ARB in Patients with CKD and Heart Failure on Maintenance Hemodialysis (MHD) (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO0501; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Sacubitril / Valsartan ( ARNI ) has shown benefits in heart failure , but it's efficacy and safety in this population remain under explored Methods This was a hospital based ,single centre ,randomised prospective study comparing sacubitril valsartan with Telmisartan in 88 adults patients with stage 5 ckd on MHD and EF<50%. Treatment was significantly related to NYHA (p value <0.01). ARNI appears to be superior to ARB therapy in improving cardiac function and clinical symptoms in patents with advanced CKD on HD and HFrEF"
Clinical • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Heart Failure • Nephrology • Renal Disease
|
|
Bibek Maulik; Atanu Pal; Arabinda Das; Priyangani Lohia; Rima Mahapatra
|